Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Epidemiology. 2014 May;25(3):406–417. doi: 10.1097/EDE.0000000000000041

Figure 1.

Figure 1

Figure 1

Active-comparator, new-user study design. HIV-positive patients who were initiators of combination antiretroviral therapy (cART) in the North Carolina Medicaid program between 2002 and 2008.

A.) Comparisons of the nucleoside reverse transcriptase inhibitors abacavir and tenofovir with any anchor antiretroviral plus lamivudine/emtricitabine (standard of care; Group 1).

B.) Comparisons of specific anchor antiretrovirals (the protease inhibitors atazanavir [Group 1] or lopinavir-ritonavir [Group 2] vs. any non-nucleoside reverse transcriptase inhibitor) plus lamivudine/emtricitabine and any nucleoside reverse transcriptase inhibitor.